Sage Therapeutics Inc
(FRA:SG7)
€
5.452
0.102 (1.91%)
Market Cap: 325.18 Mil
Enterprise Value: -211.07 Mil
PE Ratio: 0
PB Ratio: 0.61
GF Score: 49/100 SAGE Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 07:40PM GMT
Release Date Price:
€41.26
(+1.30%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
All right, go ahead and get started. Thanks, everyone, for joining. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research. This is the fireside chat with Sage Therapeutics. Happy to have with me CEO, Barry Greene. Barry, thanks for joining us.
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
Thanks for having us. Appreciate you and Morgan Stanley for doing this.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Of course. Let me quickly read a disclosure before we get started. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot